Swedish Orphan Biovitrum AB (publ) (STO:SOBI)
Sweden · Delayed Price · Currency is SEK 457.40
-1.00 (-0.22%)
Jul 24, 2026, 5:29 PM CET
STO:SOBI Financials Overview
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 30,623 | 28,238 | 26,027 | 22,123 | 18,790 | 15,529 |
Revenue Growth | 13.54% | 8.49% | 17.65% | 17.74% | 21.00% | 1.76% |
Gross Profit Gross Profit Growth | 23,810 | 21,986 | 20,242 | 17,128 | 14,014 | 12,045 |
Operating Income Operating Income Growth | 1,995 | 867 | 5,625 | 4,066 | 3,813 | 3,733 |
Net Income Net Income Growth | 1,382 | 478 | 3,885 | 2,409 | 2,638 | 2,679 |
Earnings Per Share EPS Growth | 3.93 | 1.37 | 11.24 | 7.39 | 8.44 | 9.03 |
EPS Growth | -68.78% | -87.81% | 52.10% | -12.44% | -6.53% | -17.16% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Specialty Care Specialty Care Growth | 1,447 | 1,312 | 1,267 | 1,119 | 1,280 | 1,213 |
Haematology Haematology Growth | 20,826 | 19,116 | 16,429 | 13,370 | 10,831 | 8,536 |
Immunology Immunology Growth | 8,349 | 7,809 | 8,332 | 7,635 | 6,679 | 5,780 |
Total Total Growth | 30,622 | 28,237 | 26,028 | 22,124 | 18,790 | 15,529 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 1,082 | 1,041 | 1,140 | 904 | 1,361 | 1,045 |
Total Debt Total Debt Growth | 17,587 | 11,495 | 16,735 | 20,485 | 9,101 | 10,906 |
Net Cash (Debt) Net Cash Growth | -16,505 | -10,454 | -15,595 | -19,581 | -7,740 | -9,861 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -47.29 | -30.07 | -45.13 | -60.07 | -24.77 | -33.22 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 7,859 | 8,565 | 7,388 | 4,470 | 4,576 | 5,470 |
Capital Expenditures CapEx Growth | -110 | -139 | -255 | -873 | -72 | -47 |
Free Cash Flow Free Cash Flow Growth | 7,749 | 8,426 | 7,133 | 3,597 | 4,504 | 5,423 |
Free Cash Flow Growth | 18.13% | 18.13% | 98.30% | -20.14% | -16.95% | 11.01% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 77.75% | 77.86% | 77.77% | 77.42% | 74.58% | 77.56% |
Operating Margin | 6.51% | 3.07% | 21.61% | 18.38% | 20.29% | 24.04% |
Pretax Margin | 4.04% | 0.12% | 16.93% | 13.35% | 17.67% | 21.22% |
Profit Margin | 4.52% | 1.69% | 14.90% | 10.89% | 14.04% | 17.25% |
FCF Margin | 25.30% | 29.84% | 27.41% | 16.26% | 23.97% | 34.92% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jul '26 Jul 26, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 115.63 | 242.92 | 28.24 | 36.13 | 25.56 | 20.50 |
Forward PE | 21.82 | 19.17 | 25.06 | 32.77 | 19.95 | 24.22 |
P/FCF Ratio | 20.28 | 13.65 | 15.28 | 25.22 | 14.18 | 10.07 |
PS Ratio | 5.19 | 4.07 | 4.19 | 4.10 | 3.40 | 3.52 |